false
OasisLMS
Catalog
Concurrent Paper Session II
2021 AM Concurrent Paper Session I Video
2021 AM Concurrent Paper Session I Video
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Thank you to Dr. Yarmir Mikael for presenting data on patient characteristics, prescription patterns, and alcohol use relapse among patients with insomnia associated with alcohol cessation. This study utilized the IBM MarketScan database and found that treating insomnia in patients with alcohol use disorder who are in remission significantly reduces the likelihood of alcohol relapse. Dr. Mikael highlighted the high rates of insomnia and the increased risk of relapse in early recovery from alcohol use disorder, as well as the lack of real-world evidence on the impact of insomnia treatment on alcohol relapse. The study's findings suggest the importance of addressing insomnia in patients with alcohol use disorder to aid in their recovery.<br /><br />Thank you to Celeste Wong for presenting an analysis of the impact of telehealth within a hybrid care model on treatment retention and engagement in patients with substance use disorders. The study focused on the use of telehealth during the COVID-19 pandemic and found that patients who utilized telehealth, specifically with synchronous video connection, were less likely to drop out of care and had higher treatment retention rates compared to those who used telephone services or primarily in-person visits. The study's findings support the use of telehealth in substance use treatment models and advocate for relaxation of telehealth regulations for substance use treatments.<br /><br />Thank you to Teresa Kauf for presenting data on treatment patterns and healthcare resource use among US veterans initiating medications for alcohol dependence. The retrospective study utilized the VA's Corporate Data Warehouse and found that veterans who initiated treatment with extended-release naltrexone had longer time to treatment discontinuation and better adherence compared to other FDA-approved medications for alcohol dependence. The study also observed a shift from resource-intensive inpatient care to outpatient care, potentially reducing the cost of care and strengthening patient engagement. The findings highlight the potential benefits of extended-release naltrexone in treating alcohol dependence among veterans and support the continued use of FDA-approved medications for alcohol use disorder.
Keywords
insomnia
alcohol relapse
telehealth
treatment retention
substance use disorders
extended-release naltrexone
FDA-approved medications
veterans
×
Please select your language
1
English